European Commission blame the drug companies

Commission to market the drug companies to prevent competitors in the legal initiatives that were added.

Pharmaceutical companies take measures in accordance with law, emphasized the development and research objectives is to protect the investment says.

After the patent expired drugs for pharmaceutical companies producing cheaper versions of products into the European market are having trouble for a long time was expressed.
European Commission, the pharmaceutical manufacturers to enter the European market sometimes drugs cheaper to prevent a lot of overlap, have made application.
Commission at a time for a single drug, a full application for a patent in 1300 was done to this example.

700 cases
The European Commission's report, indicated that similar problems are experienced at the national level.

Approximately 700 patents related to open cases in the report that more than 200 brand name pharmaceutical companies in the main drug producing company to reach agreement was announced between.

More than 10 per cent of this agreement, the drug blocked the entrance to the market.

Unfair practices of the European Commission found that large penalties if drug companies could not be saved.

The Commission's report, has increased the pressure on the global pharmaceutical industry.

January 20 in the U.S. is prepared to take over the tasks of the new president Barack Obama'nın, the country is expected to work to reduce drug costs.